Medscape December 13, 2024
Annie Lennon

Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for two drugs for preventing COVID-19: a monoclonal antibody called Kavigale (sipavibart) and a self-amplifying mRNA vaccine known as Kostaive (zapomeran). The recommendations are now in line for approval by the European Commission.

The active ingredient in Kavigale is sipavibart, which is an immunoglobulin, antiviral monoclonal antibody that provides passive immunization against SARS-CoV-2 by binding its spike protein receptor binding domain.

Kostaive’s active substance is zapomeran, a self-replicating mRNA that encodes the SARS-CoV-2 spike protein. It makes more copies of itself once inside host cells following intramuscular injection. The cells can then make copies of the spike protein. This induces the production of neutralizing antibodies and a...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Healthcare System, Pharma / Biotech, Public Health / COVID
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?
PBMs push private-label biosimilars in 2025 formularies
CAR T-Cell Pioneer Plots Technology’s Next Steps
Eli Lilly Adds Alzheimer’s Care to Digital Health Platform Services
GLP-1 drug use for weight loss has soared, costing billions

Share This Article